NA Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	116 Pages	Data Bridge Market Research	May, 2022	DAABD17330360

Best Price Guarantee
Price	from $3,500
Length	116 Pages
Publisher	Data Bridge Market Research
Published Date	May, 2022
SKU	DAABD17330360

NA Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029

North-America age-related macular degeneration (AMD) market is projected to register a CAGR of 8.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:
North-America Age-Related Macular Degeneration (AMD) Market, By Types (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others) and Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the North-America age-related macular degeneration (AMD) market are:
• Growing geriatric population
• Growing prevalence of macular degeneration

Market Players

The key market players for North-America age- related macular degeneration (AMD) market are listed below:
• Novartis AG
• Bayer AG
• REGENXBIO Inc.
• Ionis Pharmaceutics
• Ocugen Inc
• Johnson & Johnson Services, Inc
• IVERIC bio
• MeiraGTx Limited
• Adverum Biotechnologies, Inc.
• Graybug Vision Inc.
• Kodiak Sciences Inc.
• Genentech Inc.

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of North America Age-related Macular Degeneration (Amd) Disease Market; 1.4 Limitations; 1.5 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 Currency And Pricing; 2.5 Dbmr Tripod Data Validation Model; 2.6 Multivariate Modelling; 2.7 Type Lifeline Curve; 2.8 Primary Interviews With Key Opinion Leaders; 2.9 Dbmr Market Position Grid; 2.10 Market End User Coverage Grid; 2.11 Vendor Share Analysis; 2.12 Secondary Sources; 2.13 Assumptions
3 Executive Summary
4 Premium Insights: 4.1 Pestel; 4.2 Porter's Five Forces Model
5 Regulatory Framework
6 Market Overview: 6.1 Drivers; 6.1.1 Rising Prevalence Of Age-related Macular Degeneration; 6.1.2 Increasing Geriatric Population; 6.1.3 Increase In Pipeline Products; 6.1.4 Increase In Strategic Initiative By Key Players; 6.2 Restraints; 6.2.1 High Cost Of Treatment And Procedures; 6.2.2 Lack Of Enough Qualified Professionals; 6.3 Opportunities; 6.3.1 Increasing Research And Development; 6.3.2 Increase In Awareness And Treatment-seeking Rate Of Amd; 6.3.3 Emerging Reimbursement Policies For The Treatment; 6.3.4 Increasing Product Approval For Age-related Macular Degeneration (Amd); 6.4 Challenges; 6.4.1 Limited Access To Treatment; 6.4.2 Stringent Government Regulations For Products
7 North America Age-related Macular Degeneration (Amd) Disease Market, By Type: 7.1 Overview; 7.2 Dry Amd; 7.3 Wet Amd; 7.3.1 Medications; 7.3.2 Anti-vegf Therapy; 7.3.3 Gene Therapy; 7.3.4 Surgery
8 North America Age- Related Macular Degeneration (Amd) Disease Market, By End User: 8.1 Overview; 8.2 Hospitals; 8.3 Specialty Clinics; 8.4 Ambulatory Surgical Centers; 8.5 Home Healthcare; 8.6 Others
9 North America Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel: 9.1 Overview; 9.2 Retail Sales; 9.2.1 Hospital Pharmacies; 9.2.2 Retail Pharmacies; 9.2.3 Others; 9.3 Direct Tender
10 North America Age-related Macular Degeneration (Amd) Disease Market, By Region: 10.1 North America; 10.1.1 U.S.; 10.1.2 Canada; 10.1.3 Mexico
11 North America Age-related Macular Degeneration (Amd) Disease Market: Company Landscape: 11.1 Company Share Analysis: North America
12 Swot Analysis
13 Company Profile: 13.1 Novartis Ag; 13.1.1 Company Snapshot; 13.1.2 Revenue Analysis; 13.1.3 Company Share Analysis; 13.1.4 Product Portfolio; 13.1.5 Recent Development; 13.1.5.1 Agreement; 13.2 Genentech, Inc.; 13.2.1 Company Snapshot; 13.2.2 Company Share Analysis; 13.2.3 Product Portfolio; 13.2.4 Recent Development; 13.3 Bayer Ag; 13.3.1 Company Snapshot; 13.3.2 Revenue Analysis; 13.3.3 Company Share Analysis; 13.3.4 Product Portfolio; 13.3.5 Recent Development; 13.4 Adverum Biotechnologies, Inc.; 13.4.1 Company Snapshot; 13.4.2 Revenue Analysis; 13.4.3 Product Portfolio; 13.4.4 Recent Development; 13.5 Astellas Pharma Inc.; 13.5.1 Company Snapshot; 13.5.2 Revenue Analysis; 13.5.3 Product Portfolio; 13.5.4 Recent Development; 13.6 Graybug Vision Inc.; 13.6.1 Company Snapshot; 13.6.2 Revenue Analysis; 13.6.3 Product Portfolio; 13.6.4 Recent Development; 13.7 Gensight Biologics; 13.7.1 Company Snapshot; 13.7.2 Revenue Analysis; 13.7.3 Product Portfolio; 13.7.4 Recent Developments; 13.7.4.1 Event; 13.7.4.2 Award; 13.8 Ionis Pharmaceuticals; 13.8.1 Company Snapshot; 13.8.2 Revenue Analysis; 13.8.3 Product Portfolio; 13.8.4 Recent Development; 13.8.4.1 Event; 13.9 Iveric Bio; 13.9.1 Company Snapshot; 13.9.2 Product Portfolio; 13.9.3 Recent Development; 13.10 Johnson &Johnson Services, Inc.; 13.10.1 Company Snapshot; 13.10.2 Revenue Analysis; 13.10.3 Product Portfolio; 13.10.4 Recent Development; 13.10.4.1 Collaboration; 13.11 Kodiak Sciences Inc.; 13.11.1 Company Snapshot; 13.11.2 Product Portfolio; 13.11.3 Recent Development; 13.12 Meiragtx Limited; 13.12.1 Company Snapshot; 13.12.2 Product Portfolio; 13.12.3 Recent Developments; 13.12.3.1 Events; 13.12.3.2 Award; 13.12.3.3 Collaboration; 13.13 Ocugen Inc.; 13.13.1 Company Snapshot; 13.13.2 Product Portfolio; 13.13.3 Recent Developments; 13.13.3.1 Investment; 13.13.3.2 Clinical Trial; 13.14 Pixium Vision; 13.14.1 Company Snapshot; 13.14.2 Revenue Analysis; 13.14.3 Product Portfolio; 13.14.4 Recent Development; 13.14.4.1 Award; 13.15 Regenxbio Inc.; 13.15.1 Company Snapshot; 13.15.2 Product Portfolio; 13.15.3 Recent Developments; 13.15.3.1 Event; 13.15.3.2 Collaboration; 13.15.3.3 Certification
14 Questionnaire
15 Related Reports
List Of Tables: Table 1 Various Examples Of Ophthalmic Devices Are Summarized In The Below-given Table According To Their Classification; Table 2 North America Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 3 North America Dry Amd In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 4 North America Wet Amd In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 5 North America Wet Amd In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 6 North America Medications In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 7 North America Age-related Macular Degeneration (Amd) Disease Market, By End User, 2020-2029 (Usd Million); Table 8 North America Hospitals In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 9 North America Specialty Clinics In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 10 North America Ambulatory Surgical Centers In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 11 North America Home Healthcare In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 12 North America Others In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 13 North America Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel , 2020-2029 (Usd Million); Table 14 North America Retail Sales In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 15 North America Retail Sales In Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million); Table 16 North America Direct Tender In Age-related Macular Degeneration (Amd) Disease Market, By Region, 2020-2029 (Usd Million); Table 17 North America Age-related Macular Degeneration (Amd) Disease Market, By Country, 2020-2029 (Usd Million); Table 18 North America Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 19 North America Wet Amd In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 20 North America Medications In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 21 North America Age-related Macular Degeneration (Amd) Disease Market, By End User, 2020-2029 (Usd Million); Table 22 North America Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million); Table 23 North America Retail Sales In Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million); Table 24 U.S. Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 25 U.S. Wet Amd In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 26 U.S. Medications In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 27 U.S. Age-related Macular Degeneration (Amd) Disease Market, By End User, 2020-2029 (Usd Million); Table 28 U.S. Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million); Table 29 U.S. Retail Sales In Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million); Table 30 Canada Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 31 Canada Wet Amd In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 32 Canada Medications In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 33 Canada Age-related Macular Degeneration (Amd) Disease Market, By End User, 2020-2029 (Usd Million); Table 34 Canada Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million); Table 35 Canada Retail Sales In Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel,, 2020-2029 (Usd Million); Table 36 Mexico Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 37 Mexico Wet Amd In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 38 Mexico Medications In Age-related Macular Degeneration (Amd) Disease Market, By Type, 2020-2029 (Usd Million); Table 39 Mexico Age-related Macular Degeneration (Amd) Disease Market, By End User, 2020-2029 (Usd Million); Table 40 Mexico Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million); Table 41 Mexico Retail Sales In Age-related Macular Degeneration (Amd) Disease Market, By Distribution Channel, 2020-2029 (Usd Million)
List Of Figures: Figure 1 North America Age-related Macular Degeneration (Amd) Disease Market: Segmentation; Figure 2 North America Age-related Macular Degeneration (Amd) Disease Market: Data Triangulation; Figure 3 North America Age-related Macular Degeneration (Amd) Disease Market: Droc Analysis; Figure 4 North America Age-related Macular Degeneration (Amd) Disease Market: North America Vs Regional Market Analysis; Figure 5 North America Age-related Macular Degeneration (Amd) Disease Market: Company Research Analysis; Figure 6 North America Age-related Macular Degeneration (Amd) Disease Market: Multivariate Modelling; Figure 7 North America Age-related Macular Degeneration (Amd) Disease Market: Interview Demographics; Figure 8 North America Age-related Macular Degeneration (Amd) Disease Market: Dbmr Market Position Grid; Figure 9 North America Age-related Macular Degeneration (Amd) Disease Market: End User Coverage Grid; Figure 10 North America Age-related Macular Degeneration (Amd) Disease Market: Vendor Share Analysis; Figure 11 North America Age-related Macular Degeneration (Amd) Disease Market: Segmentation; Figure 12 North America Is Expected To Dominate And Europe Is Growing At The Fastest Pace In North America Age-related Macular Degeneration (Amd) Disease Market In The Forecast Period Of 2022 To 2029; Figure 13 Increase In The Prevalence Of Age-related Macular Degeneration (Amd) And Growing Geriatric Population Are Driving The North America Age-related Macular Degeneration (Amd) Disease Market In The Forecast Period Of 2022 To 2029; Figure 14 Dry Amd Segment Is Expected To Account For The Largest Share Of The North America Age-related Macular Degeneration (Amd) Disease Market In 2022 & 2029; Figure 15 Drivers, Restraints, Opportunities, And Challenges Of North America Age-related Macular Degeneration (Amd) Disease Market; Figure 16 North America Age-related Macular Degeneration (Amd) Disease Market: By Type, 2021; Figure 17 North America Age-related Macular Degeneration (Amd) Disease Market: By Type, 2022-2029 (Usd Million); Figure 18 North America Age-related Macular Degeneration (Amd) Disease Market: By Type, Cagr (2022-2029); Figure 19 North America Age-related Macular Degeneration (Amd) Disease Market: By Type, Lifeline Curve; Figure 20 North America Age-related Macular Degeneration (Amd) Disease Market: By End User, 2021; Figure 21 North America Age-related Macular Degeneration (Amd) Disease Market: By End User, 2022-2029 (Usd Million); Figure 22 North America Age-related Macular Degeneration (Amd) Disease Market: By End User, Cagr (2022-2029); Figure 23 North America Age-related Macular Degeneration (Amd) Disease Market: By End User, Lifeline Curve; Figure 24 North America Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, 2021; Figure 25 North America Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, 2022-2029 (Usd Million); Figure 26 North America Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, Cagr (2022-2029); Figure 27 North America Age-related Macular Degeneration (Amd) Disease Market: By Distribution Channel, Lifeline Curve; Figure 28 North America Age-related Macular Degeneration (Amd) Disease Market : Snapshot (2021); Figure 29 North America Age-related Macular Degeneration (Amd) Disease Market : By Country (2021); Figure 30 North America Age-related Macular Degeneration (Amd) Disease Market : By Country (2022 & 2029); Figure 31 North America Age-related Macular Degeneration (Amd) Disease Market : By Country (2021 & 2029); Figure 32 North America Age-related Macular Degeneration (Amd) Disease Market : By Type (2022-2029); Figure 33 North America Age-related Macular Degeneration (Amd) Disease Market: Company Share 2021 (%)